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Abstract
Background: Potentially Preventable Hospitalizations (PPH) are hospital admissions for conditions which are
preventable with timely and appropriate outpatient care being Chronic Obstructive Pulmonary Disease (COPD)
admissions one of the most relevant PPH. We estimate the population age-sex standardized relative risk of
admission for COPD-PPH by year and area of residence in the Spanish National Health System (sNHS) during the
period 2002–2013.
Methods: The study was conducted in the 203 Hospital Service Areas of the sNHS, using the 2002 to 2013 hospital
admissions for a COPD-PPH condition of patients aged 20 and over. We use conventional small area variation
statistics and a Bayesian hierarchical approach to model the different risk structures of dependence in both space
and time.
Results: COPD-PPH admissions declined from 24.5 to 15.5 per 10,000 persons-year (Men: from 40.6 to 25.1; Women:
from 9.1 to 6.4). The relative risk declined from 1.19 (19 % above 2002–2013 average) in 2002 to 0.77 (30 % below
average) in 2013. Both the starting point and the slope were different for the different regions. Variation among
admission rates between extreme areas dropped from 6.7 times higher in 2002 to 4.6 times higher in 2013.
Conclusions: COPD-PPH conditions in Spain have undergone a strong decline and a reduction in geographical
variation in the last 12 years, suggesting a general improvement in health policies and health care over time.
Variability among areas still remains, with a substantial room for improvement.
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Background
Potentially Preventable Hospitalizations (PPH) are hos-
pital admissions for certain acute illnesses or worsening
chronic conditions that may be theoretically preventable
with timely and appropriate outpatient care [1, 2]. PPH
rely on hospital discharge data but are intended as
indirect indicators of accessibility to high-quality out-
patient care [3–5]. Despite a recent decline in smoking
habits and age-adjusted mortality rates [6, 7], Chronic
Obstructive Pulmonary Disease (COPD) remains a
leading cause of morbidity and mortality [8]. Because
appropriate, continuous and well-organized outpatient
care in COPD patients could improve symptoms, re-
duce severity and avoid hospitalization, most COPD
hospital admissions are incorporated into the set of
PPH indicators [2], and in fact COPD hospitalizations
are one of the most relevant PPH, providing between a
third and a half of all cases of chronic PPHs in Spain
[3, 4] and Europe [5].
Access to care and quality varies between areas and re-
gions [9, 10]. Most PPH studies in COPD use small area
variation analysis, disease mapping or other methods to
show geographical variations in hospital admissions at a
particular time, and/or to relate this variation to demo-
graphic or social factors, the supply of health services,
physician practice styles or risk exposure [11–15]. But
accessibility to high-quality healthcare can also change
over time, and with a variable rhythm between areas
served by different healthcare organizations. However,
time trends for COPD-PPH have barely been studied
and, to our knowledge, no study has simultaneously ana-
lyzed spatial and temporal variability in COPD-PPH.
Understanding geographical variations and trends in
COPD-PPH is important for assessing accessibility to
appropriate care and also for formulating public health
initiatives to reduce the burden of this disease. The ob-
jectives of this study were to estimate the population age
and sex standardized relative risk (RR) of hospitalization
for COPD-PPH by year and area of residence in the
Spanish National Health System (sNHS) during the
period 2002–2013, and to describe its average trends
and the evolution of its spatial heterogeneity.
Methods
Design
Population based spatio-temporal study using “hospital
service areas” (HSAs) as a unit of analysis.
Setting
The study was conducted in the sNHS, a decentralized
structure of 17 regional National Health Services (NHS)
administered by the 17 Autonomous Governments of
the Spanish regions [16, 17]. During the study period
healthcare coverage was almost universal. Regional
NHSs operate an extensive network of hospitals (about
75 % of acute hospital beds in Spain), and specialized
outpatient and primary healthcare centres. Healthcare in
this network is free of charge (except for co-payment for
outpatient prescriptions) and supported by Regional
Government budgets. In 2013 the 17 sNHS regions were
organized into 203 HSAs, geographical territories –most
of them between 150,000 and 250,000 people– served by
one NHS hospital that provides specialized inpatient and
outpatient care to the residents in its area. Primary care is
Table 1 Number of COPD-PPH admissions and standardized rates in people aged 20 and over in the Spanish National Health System
(rates by 10,000 person-year; 2002–2013)
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
Population aged 20+ (n, millions) 33.34 34.13 34.66 35.45 36.09 36.53 37.15 37.49 37.67 37.79 37.86 37.75
Population aged 65+ (%) 21.60 21.41 21.17 20.79 20.80 20.69 20.61 20.84 21.01 21.37 21.67 22.03
Hospitalizations (n) 75 036 77 893 72 276 80 027 68 623 77 195 72 647 70 952 64 583 65 315 64 932 61 348
Men 60 485 63 180 58 642 65 176 55 959 62 813 58 901 57 384 51 981 52 364 51 592 48 193
Women 14 551 14 713 13 634 14 851 12 664 14 382 13 746 13 568 12 602 12 951 13 340 13 155
% Women 19.37 18.91 18.87 18.58 18.48 18.68 18.95 19.13 19.53 19.86 20.57 21.49
Patients’ age (mean, years) 73.17 73.32 73.58 73.94 73.86 74.16 74.25 74.05 73.76 74.26 74.60 74.21
Men 72.84 73.00 73.34 73.76 73.84 74.19 74.27 74.24 73.95 74.51 74.94 74.68
Women 74.53 74.66 74.61 74.76 73.94 74.03 74.16 73.22 72.99 73.26 73.28 72.50
Standardized Rate 10,000 p-y 24.46 24.70 22.13 24.05 20.19 22.24 20.45 19.42 17.26 17.03 16.64 15.53
Men 40.62 41.03 36.89 40.21 33.97 37.11 34.20 32.29 28.60 28.07 27.19 25.11
Women 9.07 9.13 8.07 8.65 7.05 8.06 7.35 7.16 6.45 6.50 6.59 6.40
Relative Risk of admission 1.19 1.22 1.11 1.19 1.02 1.11 1.03 0.98 0.86 0.85 0.83 0.77
Relative Risk in relation to the whole 2002–2013 hospitalization rate
COPD-PPH Chronic Obstructive Pulmonary Disease for Potentially Preventable Hospitalizations, p-y persons-years
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organized into local zones –most of them between 5000
and 25,000 people– associated to their respective HSA.
Due to these organizational characteristics (geographical
planning, minimal accessibility barriers, and the practical
absence of economic incentives to providers), patients re-
ceive most of their inpatient and outpatient care in the
HSA where they live.
Sources of data
The Minimum Basic Hospital Discharge Dataset of the
Regional NHSs from 2002 to 2013 was used to search
for COPD-PPH admissions. This database provides clin-
ical and sociodemographic information on all hospital
discharges in the sNHS, including diagnoses and proce-
dures coded according to the International Classification
of Diseases 9th revision Clinical Modification (ICD9CM).
The population denominators for each year were obtained
from the annual census of the Spanish National Institute
of Statistics.
Population
All 2002 to 2013 hospital admissions of patients aged
20 and over for a COPD-PPH condition defined as
following the Spanish validation [18, 19] of the US
Agency for Healthcare Research and Quality Prevention
Quality Indicators [2]. This Spanish version is similar to
the US version (see Additional file 1, e-Appendix 1 for dif-
ferences between versions) but with some ICD9CM codes
adapted to the most common codification patterns in the
sNHS and have been used in previous studies [5, 20, 21].
Main endpoint
Age-sex standardized rates of COPD-PPH by 10,000
persons-years (men, women and total) for each HSA.
Fig. 1 Distribution of COPD-PPH standardized rates among Hospital Service Areas for the overall population, men and women (Spanish NHS,
2002–2013). Foot: COPD-PPH: Chronic Obstructive Pulmonary Disease for Potentially Preventable Hospitalizations; NHS: National Health System.
Gray lines represent deciles and coloured lines the median (red) and the mean (blue)
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Analysis
First, all 2002 to 2013 COPD-PPH admissions of pa-
tients aged 20 and over were selected, linked to their
HSA of residence and aggregated into 14 age-sex groups
(20–44, 45–64, 65–69, 70–74, 75–79, 80–84, 85 and
over, for both genders). Age-sex standardized rates were
calculated by applying age-sex specific weights represent-
ing the importance of each group in the overall population
of each area. Variation among HSAs was assessed through
the ratio between the 95th and 5th percentiles, the ratio be-
tween the 75th and 25th percentiles and the coefficient of
variation of the COPD-PPH standardized rates per 10,000
persons-year. Under the hypothesis that risk remains
constant in space and time, the expected number of cases
per HSA was estimated by applying the rate for all areas
over the 12 years to the population at risk in each HSA in
the respective year. Standardized Hospitalization Ratios
(SHRs) were estimated using the ratio of observed-to-
expected cases, interpretable as the maximum estimate of
the risk ratio of admissions for a COPD-PPH in that area
in that period.
We use a Bayesian hierarchical approach to model the
different risk structures of dependence in both space
and time. In the first level of this hierarchical modeliza-
tion, we assume that, conditional on the underlying rela-
tive risk, the number of counts yjt in the j th area at the
t th time period follows a Poisson distribution with
mean ujt = ejt rjt, where ejt is the number of expected
counts and rjt the unknown relative risk. In the second
level, the log(rij) was expressed as the sum of the compo-
nents representing the individual and independent con-
tributions to the risk in a specific HSA and period
[log(rij) = intercept + Si + Tj + STij], where the intercept
term gives the initial level of risk that is shared by all re-
gions and periods. The main effects Si and Tj represent
the additional risk of living in region i and period j and
the second order interaction term STij represent the
risk contribution due to a combination of the effects
that cannot be explained additively by the main effects.
In the third level, a hyperparameter-prior distribution
was assumed where the spatial effect was modelled fol-
lowing a convolution CAR prior [22]. The temporal
main effect was a combination of a time-unstructured
(exchangeable) and a time structured effects (first
order random walk), and the interaction term can be
thought of as the independent unobserved covariates
for each combination of region and period (i,j), thus
without any structure (Type I in the Knorr-Held classi-
fication) [23] .
As a summary measure of the uncertainty surrounding
the estimate of relative risk, the posterior expected exce-
dence probability (Pr(RR > 1)) is represented [24]. Inte-
grated nested Laplace approximations (INLAs) were
used as a tool for Bayesian inference [25]. For this
Fig. 2 Age-sex adjusted relative risk of being hospitalized for a COPD-PPH condition for the overall population, men and women (Spanish NHS,
2002–2013). Foot: COPD-PPH: Chronic Obstructive Pulmonary Disease for Potentially Preventable Hospitalizations; NHS: National Health System
Librero et al. BMC Health Services Research  (2016) 16:367 Page 4 of 10
purpose, we used R-INLA with the option of simplified
Laplace estimation of the parameters, a package available
in the R environment [26].
Results
COPD-PPH admissions in people aged 20 and over de-
clined from 75,036 to 61,348 during the study period
(Table 1, Fig. 1), more markedly in men (from 60,485 to
48,193; −20.32 %) than women (from 14,551 to 13,155;
−9.59 %). Women’s hospitalizations increased from 19.4
to 21.5 % (+10.9 %) and the patients’ mean age increased
from 73,2 to 74,2 years old at the expense of men (from
72,8 to 74,7 years old vs. a decrease from 74,5 to 72,5 in
women). Because the population over 20 rose in this
period from 33.3 million in 2002 to nearly 37.7 million
in 2009, COPD-PPH age-sex standardized rates declined
more sharply: from 24.5 to 15.5 per 10,000 py (−36.7 %;
from 40.6 to 25.1, −38.2 % in men, and from 9.1 to 6,4,
−29.7 % in women).
Figure 2 displays the age-sex adjusted relative risk of
being hospitalized for a COPD-PPH condition through-
out the study period compared with the average rate
over the 12 years studied. This RR, clearly descending
throughout almost the whole period, ranged from 1.19
(19 % above the 2002–2013 average) in 2002 to 0.77
(30 % below average) in 2013, but for women the down-
ward trend flattens out in the final years. Both the start-
ing point and the slope were different for the different
regions (Fig. 3), with a strong reduction in variability
during the study period. For specific trends for Autono-
mous Regions, gender and age groups see Additional file 2,
e-Appendix 2.
Regarding variation among HSAs (Table 2), the stan-
dardized rate for the HSA in the P95 was 6.7 times
Fig. 3 Evolution of COPD-PPH standardized rates by Autonomous Communities (Spanish NHS, 2002–2013). Foot: COPD-PPH: Chronic Obstructive
Pulmonary Disease for Potentially Preventable Hospitalizations; NHS: National Health System
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higher than the HSA in the P5 in 2002, while in 2013
this difference was reduced to 4.6 times higher. The ra-
tio between HSAs in the P75 and P25 and the coefficient
of variation confirms the variability in descent among
HSAs. Violin graphs (Fig. 1) also visually show this double
phenomenon of both strong decline and convergence in
admission rates among HSAs.
Figure 4 displays the spatial patterns in standardized
rates of COPD-PPH for the entire, male and female
population. The left-hand maps show the COPD-PPH
admission spatial risk associated to each HAS to be
constant along the period. The right-hand map shows
the posterior probability that this spatial risk will be
higher than 1 (probabilities above 0.8 indicate high-risk
HSAs), which seems to concentrate on the Northern
coast, the Mediterranean coast and the central eastern
area of Spain. See Additional file 3, e-Appendix 3 for
the spatio-temporal evolution of COPD-PPH risks for
each HSA.
Discussion
Our study primarily shows a large decline in the rate of
admissions for COPD-PPH during the study period. This
descending trend is consistent with other work in Spain
restricted to hospitalization for COPD exacerbations dur-
ing the period 2006–2010 [27], but studies in the USA
(2001–2012) do not show changes in COPD admission or
emergency room visits [28] and in other countries like
France (1998–2007) rates have even increased [29]. Other
studies in Brazil (1998–2008) [30], Finland (1998–2007)
[31], and Australia (1993–2003) [32] show declining
hospitalization rates, but sometimes only for men and less
pronounced than those found in this study.
Possible causes of this sharp decline are probably di-
verse and include changes in the therapeutical manage-
ment of COPD (increases in the utilization of inhaled
long-acting beta-agonists, long-acting muscarinic antag-
onists, and inhaled corticosteroids), improvements in
influenza vaccination coverage for high-risk patients,
and organizational changes in the hospital accident and
emergency departments reducing the volume of emer-
gency hospital admissions for chronic exacerbations
(introduction of observation units and higher coordin-
ation with Hospital at Home Units and Long Term Care
Centres) [33]. Also, Primary Care Centres and Respira-
tory Medicine Departments in some HSAs have initiated
disease management or case management programs for
several chronic conditions, including COPD. [34] In this
period Spain passed two smoking laws (2006, 2011)
banning tobacco in workplaces and other public spaces.
Furthermore, the severe economic crisis entailed a signifi-
cant reduction in family income and a notable increase in
excise duties on tobacco, resulting in a marked decline in
cigarette consumption that perhaps affected patients with
Table 2 Variation in standardized rates of COPD-PPH admissions in people aged 20 and over in the Spanish National Health System
(2002–2013)
Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013
All
Rate 10000 p-y, HSA in the 10th Percentile 9.82 10.47 9.70 11.36 9.45 10.23 10.69 9.49 7.84 8.21 7.44 7.89
Rate 10000 p-y, HSA in the 90th Percentile 41.94 41.62 36.59 39.33 32.16 38.16 33.37 31.19 27.74 26.24 26.15 23.95
Ratio between 95th/5th Percentiles 6.86 4.97 5.57 5.07 4.66 4.75 4.52 5.11 4.71 4.48 4.21 4.62
Ratio between 75th/25th Percentiles 2.11 2.00 1.89 1.93 1.85 1.91 1.69 1.79 1.82 1.74 1.77 1.79
Coefficient of Variation 0.53 0.48 0.48 0.47 0.47 0.47 0.43 0.43 0.45 0.41 0.42 0.41
Men
Rate 10000 p-y, HSA in the 10th Percentile 15.98 17.45 17.37 19.75 16.52 16.80 17.14 15.68 13.14 14.28 12.35 12.58
Rate 10000 p-y, HSA in the 90th Percentile 71.83 62.93 59.70 64.68 54.16 62.33 56.67 50.93 47.41 44.30 43.55 39.84
Ratio between 95th/5th Percentiles 6.61 4.85 5.38 4.61 4.46 5.00 4.33 5.36 4.74 4.60 4.48 4.81
Ratio between 75th/25th Percentiles 2.07 1.90 1.81 1.90 1.84 1.74 1.73 1.72 1.76 1.72 1.72 1.81
Coefficient of Variation 0.52 0.47 0.48 0.47 0.47 0.47 0.43 0.43 0.45 0.41 0.43 0.42
Women
Rate 10000 p-y, HSA in the 10th Percentile 2.84 2.98 3.06 3.10 2.26 2.76 2.86 2.84 2.37 2.50 2.53 2.59
Rate 10000 p-y, HSA in the 90th Percentile 17.56 16.82 14.74 16.19 12.68 14.37 12.78 12.67 11.24 11.20 11.26 10.45
Ratio between 95th/5th Percentiles 10.75 9.23 9.57 7.74 9.34 9.73 6.02 7.53 7.81 6.90 7.16 6.11
Ratio between 75th/25th Percentiles 2.65 2.75 2.27 2.13 2.39 2.43 2.02 2.13 2.20 2.17 2.19 2.04
Coefficient of Variation 0.69 0.66 0.62 0.63 0.62 0.63 0.54 0.58 0.58 0.55 0.53 0.49
COPD-PPH Chronic Obstructive Pulmonary Disease admissions for Potentially Preventable Hospitalizations, HSA Health Service Areas, p-y persons-years
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established COPD (on average, of lower socioeconomic
strata) more heavily.
All these policies were active in Spain at the end of the
study period but they started at different times, in some
cases with a defined starting point, in other incrementally
over time. Some policies (e.g., changes in admission cri-
teria) would have a direct effect on admission rates, while
other (e.g., anti-smoking laws) would have to be mediated
through a reduction in the number of smokers or in the
average tobacco consumption. We think that, on a down-
ward trend derived from better management of COPD
and a secular reduction in the tobacco consumption in
adult males, changes in hospital admission criteria have
been the main determinant of the reduction in COPD ad-
mission rates, while the impact of smoking laws could be
gradually visible in the near future. But our data do not
allow an estimation of the impact, if any, of each one of
these cumulative number of different policies on COPD-
PPH rates.
Regarding geographical variation among HSAs, this also
experienced a meaningful decrease by compression of the
highest rates, but significant variability still remains. For
Fig. 4 Spatial patterns in standardized rates of COPD-PPH by Health Service Areas for the entire population, men and women (Spanish NHS,
2002–2013). Foot: COPD-PPH: Chronic Obstructive Pulmonary Disease for Potentially Preventable Hospitalizations; NHS: National Health System.
The left-hand maps show the COPD-PPH admission spatial risk associated to each Health Service Areas to be constant along the period. The
right-hand map shows the posterior probability that this spatial risk will be higher than 1 (probabilities above 0.8 indicate high-risk areas)
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example, with the 2013 rates in the HSA on the 90th
percentile, the sNHS would have made around 90,000
COPD-PPH hospitalizations that year, compared to only
30,000 with the rates of the HSA on the 10th percentile.
The regions with the highest rates of hospitalization
(Catalonia, Asturias, Basque country) experienced the
largest reductions. Interestingly, Andalusia, coming from
one of the lowest rates of hospitalization, also experienced
a significant reduction.
Among the study limitations, it is first worth noting
that hospitalizations in private hospitals were not in-
cluded, reducing overall hospitalization rates. The im-
portance of this bias is difficult to quantify because most
private Spanish hospitals specialize in elective surgery
and deliveries than in chronic conditions, but according
to the Spanish Hospital Morbidity Survey 21 % of all
hospitalizations for COPD in 2013 were carried out in
private hospitals [35]. Both PPH and private provision of
health care are associated with socio-economic level,
and the private sector serves most of the employees of
the Spanish Central Government (not employees of the
regional Governments) that are concentrated in certain
HSAs (provincial capitals and the Region of Madrid).
Second, hospital admission rates, even standardized by
age and sex, do not fully account for the differences in dis-
ease prevalence between areas or in the distribution of
particularly vulnerable subpopulations [36, 37]. Third,
the use of a Spanish PPH definition [18, 19] increases
the internal study validity, but limits the contrast of
our results with studies that used other definitions.
Conclusions
PPH have been adopted (and adapted) by different national
and international organizations [38–40] and are currently a
common and increasingly used instrument for the evalu-
ation of health care [41, 42]. In Europe, where insurance
tends to be universal and primary care is well developed,
PPH are interpreted not only as a measure of outpatient
care quality, but also of hospitals role in the control of
chronic patients (discharging patients who are more or less
stable, deciding which patients are admitted, etc.) and
proper coordination between different levels of care [43].
Our study shows that COPD-PPH conditions in Spain
have undergone a strong decline and a reduction in geo-
graphical variation by compression of the highest rates
in the last 12 years, suggesting a general improvement in
the management of COPD over time, specially in the HSAs
with initial higher admission rates. Causes for this improve-
ment and the relative value of each one will require further
study, but may be of interest to the development of prac-
tical policies in Spain and other countries. Nonetheless, the
remaining variability and the behaviour of some regions
that have achieved substantial declines suggests that there
is still considerable room for improvement.
Additional files
Additional file 1: CODES USED FOR IDENTIFICATION OF PPH-COPD
ADMISSIONS. Data description: description of the criteria (including
ICD-9-CM codes) for inclusion or exclusion of admissions as PPH-COPD.
(PDF 58 kb)
Additional file 2: TEMPORAL TRENDS BY AGE-GROUP, SEX AND REGION.
Data description: e-Figure 1 and e-Figure 2 show the smoothed trends of
PPH-CODP admissions stratified by four age groups and by autonomous
regions, for men and women respectively. (PDF 9601 kb)
Additional file 3: SPATIO-TEMPORAL EVOLUTION OF THE COPD
HOSPITALIZATION RISKS. Data description: e-Figure 1 displays the
spatiotemporal evolution of COPD-PPH hospitalization relative risk for
each Health Service area compared to the Spain average over the
whole period, and e-Figure 2 the posterior probabilities that these
relative risks were higher than 1. (PDF 6214 kb)
Abbreviations
COPD, chronic obstructive pulmonary disease; HSA, hospital service areas;
ICD9CM, International Classification of Diseases 9th revision Clinical
Modification; NHS, National Health Service; PPH, potentially preventable
hospitalizations; RR, relative risk; sNHS, Spanish National Health System
Collaborators
The Spanish Atlas of Medical Practice Variation Research Group is formed by
Andalusia: Díaz Martínez A (Hospital Virgen del Rocio de Sevilla), Goicoechea
Salazar JA (Servicio Andaluz de Salud, Sevilla), Rivas Ruiz F, Jiménez Puente A
(Hospital Costa del Sol, Marbella), Rodríguez del Águila MM (Hospital Virgen
de las Nieves de Granada), Molina T, Baños E (Agencia de Evaluación de
Tecnologías Sanitarias de Andalucía); Aragon: Angulo E, Bernal Delgado E,
Comendeiro Maaløe M, Estupiñán Romero FR, García Armesto S, Launa R,
Martínez Lizaga N, Ridao M, Seral Rodríguez M (Instituto Aragonés de
Ciencias de la Salud-Instituto de Investigación Sanitaria Aragón), Abad Diez
JM, Arribas Monzón F, Beltrán Peribáñez J, Pradas Arnal F (Departamento de
Sanidad, Bienestar Social y Familia, Gobierno de Aragón); Asturias: Caicoya M,
Suárez F (Consejería de Sanidad. Principado de Asturias); Canary Islands:
Sánchez Janáriz H, Alonso Bilbao Jl, Fiuza Pérez D, (Servicio Canario de la
Salud); Cantabria: Romero G (Consejería de Sanidad). Catalonia: Marinelli M
(Agència de Qualitat i Avaluació Sanitàries de Catalunya, AQuAS), Oliva G
(Departament de Salut), Ortún Rubio V (Universitat Pompeu Fabra, Barcelona);
Salas T, Vela E (CatSalut- Servei Català de la Salut); Castilla-Leon: Sacristán
Salgado A, García Crespo J (Dirección General de Desarrollo Sanitario),
Melgosa Arcos A, Sangrador Arenas L (Dirección General de Planificación,
Calidad, Ordenación y Formación); Castilla la Mancha: García Sánchez MA
(Consejería de Sanidad y AS de Castilla-La Mancha); López Reneo R (Servicio
Salud Castilla-La Mancha, SESCAM), Galicia: Atienza Merino G, Carballeira Roca C,
Queiro T (Conselleria de Sanidade de la Xunta de Galicia), Castro Villares M
(Servicio Galego de Saúde); Estremadura: Anes del Amo Y (Gobierno de
Extremadura), Montes Salas G (Escuela de Estudios de Ciencias de la Salud);
Balearic Islands: Castaño Riera EJ, Santos Terrón MJ, (Consejería de Salud);
Zaforteza Dezcallar M (Servicio de Salud de las Illes Balears), Ferrer Riera J, Martín
Martín MV (Hospital Son Llàtzer); Rioja: Cestafé A (Consejería de Salud); Madrid:
Bienzobas López C, Gómez Lázaro R (Dirección General de Sistemas de
Información Sanitaria, SERMAS); Murcia: Palomar Rodríguez J, Hernando Arizaleta L
(Consejería de Sanidad de la Región de Murcia); Navarre: Álvarez Arruti N, Montes
García Y, Rodrigo Rincón I (Departamento de Salud de Navarra- Osasunbidea),
Ibáñez Beroiz B (Centro de Investigación Biomédica-Navarra); Basque
Country: Aizpuru F, Latorre García PM, Latorre A, Pérez de Arriba J
(Grupo de investigación del País Vasco, Osakidetza-SVS), Errezola M
(Departamento de Sanidad del Gobierno Vasco), Millán E (Osakidetza-SVS);
Valencia Community: Baixauli-Pérez C, Librero J, Peiró S, Rodríguez-Bernal CL,
Sanfelix-Gimeno G (Fundación para el Fomento de la Investigación Sanitaria y
Biomédica de la Comunidad Valenciana, FISABIO), Meneu R, Sotoca R
(Fundación Instituto de Investigación en Servicios de Salud, fIISS),
Calabuig J (Conselleria de Sanitat, Generalitat Valenciana).
Funding
This study is part of the “Atlas of Medical Practice Variation in the Spanish
National Health System” research project, funded by the Instituto de Salud
Librero et al. BMC Health Services Research  (2016) 16:367 Page 8 of 10
Carlos III (Grants G03/202, PI05/2490, PI06/1673, PI10/00494 and PI14/
00786, with cofinancing from the European Regional Development
Fund), IBERCAJA, and the Fundación Instituto de Investigación en
Servicios de Salud. This particular study is also funded by Collaboration
Agreements in 2013 and 2014 between the Fundación para el Fomento
de la Investigación Sanitaria y Biomédica (FISABIO, Valencia Ministry of
Health) and Boehringer Ingelheim. CLRB and MRL were funded by
grants RD12/0001/0005 and RD12/0001/0004 from the Instituto de Salud
Carlos III, Spanish Ministry of Health, cofinanced by the European
Regional Development Fund.
Availability of data and material
The datasets (dat.Rdata) and programmes (COPD_bmc.Rmd) analysed during
the current study are available in the Spanish Atlas of Medical Practice
Variation Research Group repository, [http://www.atlasvpm.org/documents/
10157/87d16dac-02c3-47b4-9054-b05f78d4a0e7].
Authors’ contribution
JL and SP had full access to all the data in the study and take responsibility
for the integrity of the data and the accuracy of the data analysis. The
primary data acquisition is a collective task of the Spanish Atlas of Medical
Practice Variation Research Group, with project coordination managed by
the Aragon and Valencia research groups. JL, BIB and SP were responsible
for the study concept, design and data acquisition from the Spanish Atlas
Database. JL, MRL, FGR and CLRB carried out the data preparation and the
statistical analysis and JL, BIB, SP and EBD drafted the manuscript. All
authors participated in the analysis and interpretation of data, critical
revision of the manuscript for important intellectual content, all approved
the final version submitted for publication and agree to be accountable
for all aspects of the work in ensuring that questions related to the
accuracy or integrity of any part of the work are appropriately
investigated and resolved.
Competing interests
None of the sponsors played any role in the study design, the collection,
analysis or interpretation of data, the writing of the manuscript or in the
decision to submit it for publication. The Collaboration Agreements
between FISABIO and Boehringer Ingelheim are a non-conditioned
program for conducting independent research in chronic diseases,
pharmacoepidemiology and medical practice variation. All authors
declare no potential conflicts of interest exist with any companies/
organizations whose products or services may be discussed in this
article. Most researchers of the Spanish Atlas of Medical Practice
Variation Research Group work in centres or institutions depending
on the Health Departments of the Spanish Regional Autonomous
Governments. Neither these institutions nor the institutions or firms
funding the research project necessarily share the contents of this
manuscript.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The study, observational in design and with retrospective data irreversibly
anonymized prior to their transfer to the research team, was conducted in
accordance with the amended Helsinki Declaration, the International
Guidelines for Ethical Review of Epidemiological Studies, and Spanish laws
on data protection and patients’ rights. Due to the nature of the study
consent to participate was deemed unnecessary by the ethics committee.
The study protocol was approved by the Ethics Committee for Clinical
Research of the General Directorate of Public Health and the Centre for
Public Health Research (session on March 20, 2014).
Author details
1Centro Superior de Investigación en Salud Pública (CSISP-FISABIO),
Catalunya Av. 21, 46020 Valencia, Spain. 2Red de Investigación en Servicios
de Salud en Enfermedades Crónicas (REDISSEC), Valencia, Spain.
3NavarraBiomed - Fundación Miguel Servet, Pamplona, Spain. 4Instituto
Aragonés de Ciencias de la Salud. IIS Aragón, Zaragoza, Spain.
Received: 11 October 2015 Accepted: 3 August 2016
References
1. Billings J, Zeitel L, Lukomnik J, Carey TS, Blank AE, Newman L. Impact of
socioeconomic status on hospital use in New York City. Health Aff
(Millwood). 1993;12(1):162–73.
2. Agency for Healthcare Research and Quality. Guide to Prevention Quality
Indicators: hospital admission for ambulatory care sensitive conditions
(Version 3.1). Agency for Healthcare Research and Quality; 2007. Available at:
http://www.qualityindicators.ahrq.gov/Downloads/Modules/PQI/V31/pqi_
guide_v31.pdf. Accessed 12 Feb 2015.
3. Magán P, Alberquilla A, Otero A, Ribera JM. Hospitalizations for ambulatory
care sensitive conditions and quality of primary care: their relation with
socioeconomic and health care variables in the Madrid regional health
service (Spain). Med Care. 2011;49(1):17–23.
4. Ibañez-Beroiz B, Librero J, Bernal-Delgado E, García-Armesto S, Villanueva-
Ferragud S, Peiró S. Joint spatial modeling to identify shared patterns
among chronic related potentially preventable hospitalizations. BMC Med
Res Methodol. 2014;14:74.
5. Thygesen LC, Christiansen T, Garcia-Armesto S, Angulo-Pueyo E, Martínez-
Lizaga N, Bernal-Delgado E, ECHO Consortium. Potentially avoidable
hospitalizations in five European countries in 2009 and time trends from
2002 to 2009 based on administrative data. Eur J Public Health. 2015;25
Suppl 1:35–43.
6. Lopez-Campos JL, Ruiz-Ramos M, Soriano JB. Mortality trends in chronic
obstructive pulmonary disease in Europe, 1994–2010: a joinpoint regression
analysis. Lancet Respir Med. 2014;2(1):54–62.
7. Ford ES. Trends in mortality from chronic obstructive pulmonary disease
among adults in the United States. Chest. 2015;148(4):962–70.
8. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and
national age-sex specific all-cause and cause-specific mortality for 240
causes of death, 1990–2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet. 2015;385(9963):117-71.
9. Wennberg J, Gittelsohn A. Small area variations in health care delivery.
Science. 1973;182:1102–8.
10. Committee on Geographic Variation in Health Care Spending and
Promotion of High-Value Care; Board on Health Care Services; Institute of
Medicine, Newhouse JP, Garber AM, Graham RP, et al., editors. Variation in
Health Care Spending: Target Decision Making, Not Geography. Washington
(DC): National Academies Press (US); 2013. Available from: http://www.ncbi.
nlm.nih.gov/books/NBK201647/pdf/Bookshelf_NBK201647.pdf.
Accessed 12 Feb 2015.
11. Morris RD, Munasinghe RL. Geographic variability in hospital admission rates
for respiratory disease among the elderly in the United States. Chest.
1994;106(4):1172–81.
12. O’Malley AS, Pham HH, Schrag D, Wu B, Bach PB. Potentially avoidable
hospitalizations for COPD and pneumonia: the role of physician and
practice characteristics. Med Care. 2007;45(6):562–70.
13. Holt JB, Zhang X, Presley-Cantrell L, Croft JB. Geographic disparities in
chronic obstructive pulmonary disease (COPD) hospitalization among
Medicare beneficiaries in the United States. Int J Chron Obstruct Pulmon
Dis. 2011;6:321–8.
14. Halvorsen T, Martinussen PE. The geography of chronic obstructive
pulmonary disease: a population-based study of Norway. Soc Sci Med.
2014;111:25–34.
15. Farah C, Hosgood 3rd HD, Hock JM. Spatial prevalence and associations
among respiratory diseases in Maine. Spat Spatiotemporal Epidemiol.
2014;11:11–22.
16. Martin-Moreno JM, Alonso P, Claveria A, Gorgojo L, Peiró S. Spain: a
decentralised health system in constant flux. BMJ. 2009;338:b1170.
17. García-Armesto S, Abadía-Taira MB, Durán A, Hernández-Quevedo C, Bernal-
Delgado E. Spain: Health system review. Health Syst Transition. 2010;12(4):1–
295. Available at: http://www.euro.who.int/__data/assets/pdf_file/0004/
128830/e94549.pdf. Accessed 1 Aug 2013.
18. Validación de indicadores de calidad utilizados en el contexto internacional:
indicadores de seguridad de pacientes e indicadores de hospitalización
evitable. Madrid: Ministerio de Sanidad y Consumo; 2008. Available at:
http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/docs/Validacion_
indicadores_calidad.pdf. Accessed 1 June 2015.
Librero et al. BMC Health Services Research  (2016) 16:367 Page 9 of 10
19. Bernal-Delgado E, Peiró Moreno S, Dir. Quality of ambulatory care in the
Spanish National Health System: analysis of three OECD indicators and
some alternatives. Madrid: Ministry of Health and Consumer Affairs; 2009.
Available at: http://www.msssi.gob.es/organizacion/sns/planCalidadSNS/
docs/PQI_Spain_WP_2009.pdf. Accessed 1 June 2015
20. Abadía-Taira MB, Martínez-Lizaga N, García-Armesto S, Ridao-López M, Yañez
F, Seral-Rodríguez M, et al. Variabilidad en las Hospitalizaciones
Potencialmente Evitables relacionadas con la reagudización de
enfermedades crónicas. Atlas Var Pract Med Sist Nac Salud. 2011;4(2):345–63.
Available at: http://www.atlasvpm.org/es/atlas-visor/-/journal_content/56_
INSTANCE_Q9pH/10157/31181. Accessed 1 June 2015.
21. Martínez-Lizaga N, Montes Y, Rodrigo I, Abadía-Taira MB, Ibañez-Beroiz B,
Librero-López L, et al. Metodología del Atlas de variaciones en
Hospitalizaciones Potencialmente Evitables en el Sistema Nacional de Salud.
Atlas Var Pract Med Sist Nac Salud. 2011;4(2):371–8. Available at:
http://www.atlasvpm.org/documents/10157/27363/notasmetodologi
casatlas8_%28176KB%29.pdf. Accessed 1 June 2015.
22. Besag J, York J, Mollie A. Bayesian image restoration, with two applications
in spatial statistics. Ann Inst Statist Math. 1991;43:1–59.
23. Knorr-Held L. Bayesian modelling of inseparable space-time variation in
disease risk. Stat Med. 2000;19(17–18):2555–67.
24. Richardson S, Thomson A, Best N, Elliott P. Interpreting posterior
relative risk estimates in disease-mapping studies. Environ Health
Perspect. 2004;112(9):1016–25.
25. Rue H, Martino S, Chopin N. Approximate Bayesian inference for latent
Gaussian models using integrated nested Laplace approximations (with
discussion). J R Stat Soc Ser B. 2009;71:319–92.
26. R Development Core Team. R: A language and environment for statistical
computing. Vienna: R Foundation for Statistical Computing; 2010.
27. de Miguel-Díez J, Jiménez-García R, Hernández-Barrera V, Puente-Maestu L,
Rodríguez-Rodríguez P, López de Andrés A, et al. Trends in hospital
admissions for acute exacerbation of COPD in Spain from 2006 to 2010.
Respir Med. 2013;107(5):717–23.
28. Ford ES. Hospital discharges, readmissions, and emergency department
visits for chronic obstructive pulmonary disease or bronchiectasis among
US adults: findings from the Nationwide Inpatient Sample 2001–2012 and
Nationwide Emergency Department Sample 2006–2011. Chest. 2014.
doi:10.1378/chest.14-2146. [Epub ahead of print]
29. Fuhrman C, Roche N, Vergnenègre A, Zureik M, Chouaid C, Delmas MC.
Hospital admissions related to acute exacerbations of chronic obstructive
pulmonary disease in France, 1998–2007. Respir Med. 2011;105(4):595–601.
30. Benseñor IM, Fernandes TG, Lotufo PA. Chronic obstructive pulmonary
disease in Brazil: mortality and hospitalization trends and rates, 1996–2008.
Int J Tuberc Lung Dis. 2011;15(3):399–404.
31. Kinnula VL, Vasankari T, Kontula E, Sovijarvi A, Saynajakangas O, Pietinalho A.
The 10-year COPD Programme in Finland: effects on quality of diagnosis,
smoking, prevalence, hospital admissions and mortality. Prim Care Respir J.
2011;20(2):178–83.
32. Wilson DH, Tucker G, Frith P, Appleton S, Ruffin RE, Adams RJ. Trends
in hospital admissions and mortality from asthma and chronic
obstructive pulmonary disease in Australia, 1993-2003. Med J Aust.
2007;186(8):408-11.
33. Jeppesen E, Brurberg KG, Vist GE, Wedzicha JA, Wright JJ, Greenstone M,
et al. Hospital at home for acute exacerbations of chronic obstructive
pulmonary disease. Cochrane Database Syst Rev. 2012;5:CD003573.
34. Kruis AL, Smidt N, Assendelft WJ, Gussekloo J, Boland MR, Rutten-van
Mölken M, et al. Integrated disease management interventions for patients
with chronic obstructive pulmonary disease. Cochrane Database Syst Rev.
2013;10:CD009437.
35. Instituto Nacional de Estadística. Encuesta de Morbilidad Hospitalaria.
Avalaible at: http://www.ine.es/dyngs/INEbase/es/operacion.htm?c=Estadistica_
C&cid=1254736176778&menu=ultiDatos&idp=1254735573175.
Accessed 9 Mar 2016.
36. Peköz EA, Shwartz M, Iezzoni LI, Ash AS, Posner MA, Restuccia JD.
Comparing the importance of disease rate versus practice style variations in
explaining differences in small area hospitalization rates for two respiratory
conditions. Stat Med. 2003;22(10):1775–86.
37. Shwartz M, Peköz EA, Ash AS, Posner MA, Restuccia JD, Iezzoni LI. Do
variations in disease prevalence limit the usefulness of population-based
hospitalization rates for studying variations in hospital admissions? Med
Care. 2005;43:4–11.
38. OECD. Geographic Variations in Health Care. What Do We Know and What
Can Be Done to Improve Health System Performance?. OECD Publishing,
2014, Available at: http://www.oecd-ilibrary.org/social-issues-migration-
health/geographic-variations-in-health-care_9789264216594-en.
Accessed 1 Dec 2014.
39. Statistics Canada, Health Information and Research Division: Hospitalizations
for ambulatory care sensitive conditions (ACSC) the factors that matter.
Ottawa: Statistics Canada, Health Information and Research Division; 2011.
Available at: http://epe.lac-bac.gc.ca/100/200/301/statcan/health_research_
working_papers-e/07/82-622-x2011007-eng.pdf. Accessed 25 July 2013.
40. Department of Health. Victorian health information surveillance system
(VHISS) - ambulatory care sensitive conditions (ACSCs). Melbourne: State
Government of Victoria; 2012. Available at: https://hns.dhs.vic.gov.au/
3netapps/vhisspublicsite/ViewContent.aspx?TopicID=1&SubTopicID=10.
Accessed 1 June 2015.
41. Davies S, McDonald KM, Schmidt E, Schultz E, Geppert J, Romano PS.
Expanding the uses of AHRQ’s prevention quality indicators: validity from
the clinician perspective. Med Care. 2011;49(8):679–85.
42. Hussey PS, Mattke S, Morse L, Ridgely MS. Evaluation of the use of AHRQ
and other quality indicators (AHRQ Publication No. 08-M012-EF).
Rockville: Agency for Healthcare Research and Quality; 2007. Available
at: http://www.ahrq.gov/research/findings/final-reports/qualityindicators/
qualityindicators.pdf. Accessed 1 June 2015.
43. Peiro S, Bernal Delgado E. Avoidable hospitalizations. Who bears the burden
of proof? Rev Calidad Asistencial. 2006;21:173–5.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Librero et al. BMC Health Services Research  (2016) 16:367 Page 10 of 10
